Sun Pharma Advanced Research Company working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

2.36×	2.36×	80.33×	116.54×	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1,632.22×	1,632.22×	2,022.42×	1,870.66×	—
−1,629.86×	−1,629.86×	−1,942.09×	−1,754.12×	—
1.72×	1.70×	−0.21×	17.45×	0.90×
1.50×	1.50×	0.17×	0.11×	—
−0.15×	−0.15×	1.05×	1.11×	—
−0.15×	−0.15×	1.11×	1.07×	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SPARC₹182.98

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health

₹ CrorePeersSTAR SHILPAMED SUPRIYA THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹5,938 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Receivable Days (DSO)	—	116.54	80.33	2.36	2.36
Payable Days (DPO)	—	1,870.66	2,022.42	1,632.22	1,632.22
Cash Conversion Cycle (days)	—	-1,754.12	-1,942.09	-1,629.86	-1,629.86
Working Capital Turnover	0.90	17.45	-0.21	1.70	1.72
Asset Turnover	—	0.11	0.17	1.50	1.50
Cash Conversion (CFO/Net Income)	—	1.11	1.05	-0.15	-0.15
CFO/EBITDA	—	1.07	1.11	-0.15	-0.15

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.